Theme
GLP-1
The incretin drug class driving the obesity and diabetes supercycle.
GLP-1 receptor agonists are incretin-based therapies that improve glycemic control and drive substantial weight loss. The class underpins a rapidly expanding market spanning diabetes, obesity, and adjacent metabolic conditions.
Companies · 6
Amgen Inc.AMGN
Market cap$220B
Conviction5 / 5
GLP-1Obesity
Read profileEli Lilly and CompanyLLY
Market cap$1.0T
Conviction5 / 5
GLP-1Obesity
Read profileBachem Holding AGBANB
Market cap$7.6B
Conviction4 / 5
GLP-1Metabolic disease
Read profileNovo Nordisk A/SNVO
Market cap$128B
Conviction4 / 5
GLP-1Obesity
Read profileZealand Pharma A/SZEAL
Market cap$2.8B
Conviction3 / 5
ObesityGLP-1
Read profileStructure Therapeutics Inc.GPCR
Market cap$2.6B
Conviction2 / 5
ObesityGLP-1
Read profile